Prelude Therapeutics Incorporated Share Price

Prelude Therapeutics Incorporated Share Price

NASDAQ: PRLD | Micro Cap
$3.34
-$0.08 (-2.48%) Last updated on 18 Nov, 2026 | 02:29 IST
  • Performance
  • Chart
  • Fundamentals
  • Quarterly P&L
  • Annual P&L
  • About
  • Price history
  • FAQs

Prelude Therapeutics Incorporated Stock Performance

Open
$3.44
Prev. Close
$3.42
Circuit Range
N/A
Day Range
$3.27 - $3.50
Year Range
$1.29 - $6.82
Volume
37,698
Average Traded
$3.32

Prelude Therapeutics Incorporated Share Price Today

As of 18 November 2026, Prelude Therapeutics Incorporated's share price is $3.34. The stock opened at $3.44, compared to its previous close of $3.42. During today's trading session, Prelude Therapeutics Incorporated's share price traded between $3.27 and $3.50, with an average price of $3.38. Over the past 52 weeks, the stock has recorded a high of $6.82 and a low of $1.29. In terms of performance, Prelude Therapeutics Incorporated's share price has declined by 15.01% over the last six months and is up 99.40% on a year-on-year basis.

Prelude Therapeutics Incorporated Share Price Chart

Line chart of the Prelude Therapeutics Incorporated price trend over the selected period. The price fell overall, ranging from 3.27 to 3.50, ending at 3.34.
$3.27$3.50
L
Show Current Price
H

Prelude Therapeutics Incorporated Stock Fundamentals & Key Indicators

Market Cap
$257.03M
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-0.76
Revenue (TTM)
$12.14B
Return On Equity (TTM)
-45.23%
Profit Margin
-819.60%
Debt to Equity
0.00
Quarterly Earnings Growth YoY
29.45%

Prelude Therapeutics Incorporated Quarterly Profit & Loss

All figures in USD

ParticularsSep 2025Dec 2025Mar 2026Jun 2026
Revenue$6.50$5.64$4.58$5.70
Net Profit-$19.73-$16.46-$10.39-$13.92
Net Profit Margin-303.54%-291.84%-226.86%-244.21%
Income ChangeN/A16.57%36.88%-33.97%

Prelude Therapeutics Incorporated Annual Profit & Loss

All figures in USD

Particulars2022202320242025
Revenue$0.00$0.00$7.00$12.14
Net Profit-$115.44-$121.83-$127.17-$99.50
Net Profit MarginN/AN/A-1816.71%-819.60%
Income ChangeN/A-5.54%-4.38%21.76%

About Prelude Therapeutics Incorporated

Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.

Prelude Therapeutics Incorporated Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Nov 2026
$3.89
$3.32
-14.54%
Oct 2026
$3.77
$3.88
-0.89%
Sep 2026
$5.54
$3.92
-38.07%
Aug 2026
$4.61
$6.33
+37.31%
Jul 2026
$5.27
$4.61
-13.26%
Jun 2026
$3.86
$5.32
+35.24%
May 2026
$5.01
$3.93
-24.28%
Apr 2026
$3.60
$5.19
+52.65%
Mar 2026
$2.74
$3.40
+23.19%
Feb 2026
$1.88
$2.76
+48.39%
Jan 2026
$2.80
$1.86
-35.64%
Dec 2025
$1.52
$2.89
+72.54%

PRLD Share Price FAQs